-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Comparing DBV Technologies (NASDAQ:DBVT) & Gene Biotherapeutics (OTCMKTS:CRXM)
Comparing DBV Technologies (NASDAQ:DBVT) & Gene Biotherapeutics (OTCMKTS:CRXM)
Gene Biotherapeutics (OTCMKTS:CRXM – Get Rating) and DBV Technologies (NASDAQ:DBVT – Get Rating) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, risk and profitability.
Risk and Volatility
Gene Biotherapeutics has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, DBV Technologies has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500.
Get Gene Biotherapeutics alerts:Analyst Recommendations
This is a breakdown of recent ratings for Gene Biotherapeutics and DBV Technologies, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Gene Biotherapeutics | 0 | 0 | 0 | 0 | N/A |
DBV Technologies | 0 | 3 | 3 | 0 | 2.50 |
Valuation and Earnings
This table compares Gene Biotherapeutics and DBV Technologies' revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Gene Biotherapeutics | N/A | N/A | -$520,000.00 | N/A | N/A |
DBV Technologies | $5.71 million | 55.00 | -$97.81 million | ($0.68) | -2.46 |
Gene Biotherapeutics has higher earnings, but lower revenue than DBV Technologies.
Profitability
This table compares Gene Biotherapeutics and DBV Technologies' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Gene Biotherapeutics | N/A | N/A | N/A |
DBV Technologies | -929.78% | -57.09% | -43.02% |
Insider & Institutional Ownership
27.6% of DBV Technologies shares are owned by institutional investors. 49.8% of Gene Biotherapeutics shares are owned by insiders. Comparatively, 0.6% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Gene Biotherapeutics beats DBV Technologies on 5 of the 9 factors compared between the two stocks.
About Gene Biotherapeutics
(Get Rating)
Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.
About DBV Technologies
(Get Rating)
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Receive News & Ratings for Gene Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gene Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Gene Biotherapeutics (OTCMKTS:CRXM – Get Rating) and DBV Technologies (NASDAQ:DBVT – Get Rating) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, risk and profitability.
基因生物治疗公司(OTCMKTS:CRXM-GET Rating)和DBV Technologies(纳斯达克:DBVT-GET Rating)都是医药公司,但哪只股票更好?我们将根据分析师的建议、估值、收益、股息、机构所有权、风险和盈利能力对这两家公司进行比较。
Risk and Volatility
风险和波动性
Gene Biotherapeutics has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, DBV Technologies has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500.
Gene BioTreateutics的贝塔系数为0.73,表明其股价的波动性比标准普尔500指数低27%。相比之下,DBV Technologies的贝塔系数为1.49,这表明其股价的波动性比标准普尔500指数高49%。
Analyst Recommendations
分析师建议
This is a breakdown of recent ratings for Gene Biotherapeutics and DBV Technologies, as provided by MarketBeat.
这是MarketBeat提供的基因生物疗法和DBV技术最近的评级细目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Gene Biotherapeutics | 0 | 0 | 0 | 0 | N/A |
DBV Technologies | 0 | 3 | 3 | 0 | 2.50 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
基因生物治疗学 | 0 | 0 | 0 | 0 | 不适用 |
DBV技术 | 0 | 3 | 3 | 0 | 2.50 |
Valuation and Earnings
估值和收益
This table compares Gene Biotherapeutics and DBV Technologies' revenue, earnings per share (EPS) and valuation.
该表格比较了基因生物治疗公司和DBV技术公司的收入、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Gene Biotherapeutics | N/A | N/A | -$520,000.00 | N/A | N/A |
DBV Technologies | $5.71 million | 55.00 | -$97.81 million | ($0.68) | -2.46 |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
基因生物治疗学 | 不适用 | 不适用 | -$520,000.00 | 不适用 | 不适用 |
DBV技术 | 571万美元 | 55.00 | -9,781万元 | ($0.68) | -2.46 |
Gene Biotherapeutics has higher earnings, but lower revenue than DBV Technologies.
基因生物治疗公司的收益比DBV技术公司高,但收入较低。
Profitability
盈利能力
This table compares Gene Biotherapeutics and DBV Technologies' net margins, return on equity and return on assets.
此表比较了基因生物治疗公司和DBV技术公司的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
Gene Biotherapeutics | N/A | N/A | N/A |
DBV Technologies | -929.78% | -57.09% | -43.02% |
净利润率 | 股本回报率 | 资产回报率 | |
基因生物治疗学 | 不适用 | 不适用 | 不适用 |
DBV技术 | -929.78% | -57.09% | -43.02% |
Insider & Institutional Ownership
内部人与机构所有权
27.6% of DBV Technologies shares are owned by institutional investors. 49.8% of Gene Biotherapeutics shares are owned by insiders. Comparatively, 0.6% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
DBV Technologies 27.6%的股份由机构投资者持有。基因生物治疗公司49.8%的股份由内部人士持有。相比之下,DBV Technologies 0.6%的股份由内部人士持有。强大的机构持股表明,大型基金管理公司、捐赠基金和对冲基金相信,一家公司的长期表现将好于大盘。
Summary
摘要
Gene Biotherapeutics beats DBV Technologies on 5 of the 9 factors compared between the two stocks.
基因生物治疗公司在两只股票之间的9个因素中有5个超过了DBV Technologies。
About Gene Biotherapeutics
关于基因生物治疗学
(Get Rating)
(获取评级)
Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.
基因生物疗法公司是一家临床阶段生物技术公司,在美国专注于血管生成基因疗法生物疗法的开发和商业化,用于治疗心血管疾病。该公司的主导候选产品是Generx,这是第三阶段临床试验中的一种血管生成基因治疗候选产品,用于潜在地治疗晚期冠状动脉疾病引起的心肌缺血和顽固性心绞痛患者。它还在开发与缺血相关的心血管和脑治疗适应症的Generx。基因生物治疗公司与Fujifilm DiSynth生物技术公司达成协议,将生产用于第三阶段临床评估的Generx血管生成基因治疗产品。该公司前身为红豆杉Cardium制药集团,并于2018年1月更名为基因生物治疗公司。基因生物治疗公司成立于2003年,总部设在加利福尼亚州圣地亚哥。
About DBV Technologies
关于DBV技术
(Get Rating)
(获取评级)
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
DBV科技公司是一家临床阶段的生物制药公司,致力于皮肤表面免疫治疗产品的研究和开发。它的主要候选产品是Viaskin花生,这是一种免疫疗法产品,已经完成了治疗4至11岁儿童、青少年和成人花生过敏的第三阶段临床试验。这家牛奶公司还在开发Viaskin Milk,这是一种治疗免疫球蛋白E(IgE)介导的牛奶蛋白过敏(CMPA)的I/II期临床试验;Viaskin Egg,一种治疗母鸡鸡蛋过敏的临床前阶段产品;以及百日咳加强疫苗。它的其他早期研究项目包括呼吸道合胞病毒疫苗,以及克罗恩病、乳糜泻和I型糖尿病的治疗。该公司与雀巢́健康科学公司合作开发MAG1C,这是一种即用即用的特应性斑贴试验,用于诊断婴儿和幼儿的非免疫球蛋白E介导的CMPA。DBV技术公司成立于2002年,总部设在法国蒙图日。
Receive News & Ratings for Gene Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gene Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
获得《基因生物疗法日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对基因生物疗法和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧